title: Prevalence of antibiotic resistance in US hospitals.
abstract: The percentage of isolates resistant to essential antibiotics among clinically significant bacterial pathogens was evaluated using data from 80089 qualifying admissions in 19 US hospitals (2007-2010). Percentage resistant was highest for the following pathogen/antibiotic pairs: Enterococcus faecium/vancomycin (87.1% [95% CI 86.0-88.1] of 4024 isolates), Staphylococcus aureus/oxacillin-methicillin (56.8% [56.1-57.4] of 23477 isolates), S. aureus/clindamycin (39.7% [39.1-40.4] of 21133 isolates), Pseudomonas aeruginosa/fluoroquinolones (32.6% [31.8-33.5] of 10982 isolates), and Escherichia coli/fluoroquinolones (31.3% [30.8-31.8] of 30715 isolates). The percentage resistant was 3.9% (3.2-4.9) for E. faecium/daptomycin (n = 2029 isolates). While these results are consistent with those from earlier studies in many respects, the percentage of E. faecium isolates resistant to daptomycin, while still small, is higher than has been reported to date.
authors.affiliation: Policy Analysis Inc. (PAI), Brookline, MA, USA.
authors.forename: John
authors.initials: J
authors.lastname: Edelsberg
authors.affiliation: Policy Analysis Inc. (PAI), Brookline, MA, USA. Electronic address: dweycker@pai2.com.
authors.forename: Derek
authors.initials: D
authors.lastname: Weycker
authors.affiliation: Amgen Inc., Thousand Oaks, CA, USA.
authors.forename: Rich
authors.initials: R
authors.lastname: Barron
authors.affiliation: Amgen Inc., Thousand Oaks, CA, USA.
authors.forename: Xiaoyan
authors.initials: X
authors.lastname: Li
authors.affiliation: Policy Analysis Inc. (PAI), Brookline, MA, USA; Wentworth Institute of Technology, Department of Computer Science and Networking, Boston, MA, USA.
authors.forename: Hongsheng
authors.initials: H
authors.lastname: Wu
authors.affiliation: Policy Analysis Inc. (PAI), Brookline, MA, USA.
authors.forename: Gerry
authors.initials: G
authors.lastname: Oster
authors.affiliation: Amgen Inc., Thousand Oaks, CA, USA.
authors.forename: Sejal
authors.initials: S
authors.lastname: Badre
authors.affiliation: Amgen Inc., Thousand Oaks, CA, USA.
authors.forename: Wendy J
authors.initials: WJ
authors.lastname: Langeberg
authors.affiliation: University of North Carolina at Chapel Hill, Schools of Medicine and Public Health, Chapel Hill, NC, USA.
authors.forename: David J
authors.initials: DJ
authors.lastname: Weber
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D024901:Drug Resistance, Multiple, Bacterial; D016984:Enterococcus faecium / Q000187:drug effects; D004926:Escherichia coli / Q000187:drug effects; D005260:Female; D016905:Gram-Negative Bacterial Infections / Q000188:drug therapy / Q000453:epidemiology*; D016908:Gram-Positive Bacterial Infections / Q000188:drug therapy / Q000453:epidemiology*; D006761:Hospitals; D006801:Humans; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D015995:Prevalence; D011550:Pseudomonas aeruginosa / Q000187:drug effects; D013211:Staphylococcus aureus / Q000187:drug effects; D014481:United States / Q000453:epidemiology; D055815:Young Adult
chemical_list: D000900:Anti-Bacterial Agents
keywords: Antibiotics; Bacterial; Drug resistance